{"gene":"CD160","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1998,"finding":"CD160 (BY55) is a GPI-anchored, cysteine-rich protein of 181 amino acids with a single Ig-like domain weakly homologous to killer inhibitory receptors. Reduction and carboxyamidomethylation of immunoprecipitated BY55 gave a 27 kDa band, whereas reduction alone gave 80 kDa, indicating CD160 forms tightly disulfide-linked multimers. Expression is restricted to CD56dim/CD16+ NK cells (high cytolytic activity) but not CD56bright/CD16- NK cells, and to CD8+CD28- T cells and intestinal intraepithelial lymphocytes.","method":"cDNA cloning, immunoprecipitation with reducing/non-reducing SDS-PAGE, RNA blot analysis, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — molecular cloning with biochemical characterization (immunoprecipitation, reduction/alkylation) establishing multimeric GPI-anchored structure; replicated across multiple methods in single rigorous study","pmids":["9743336"],"is_preprint":false},{"year":2002,"finding":"CD160 receptor engagement by HLA-C molecules (constitutively expressed on K562 cells) triggers NK cell cytolytic activity. Direct interaction between recombinant soluble HLA-Cw3 and CD160 proteins was demonstrated. CD158b inhibitory receptors partially interfere with CD160-mediated cytotoxicity, whereas CD94/CD159a and CD85j do not.","method":"Monoclonal antibody blocking assays, cytotoxicity assays, recombinant protein binding (soluble HLA-Cw3 and CD160), flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct protein-protein interaction shown with recombinant proteins plus functional cytotoxicity assay with antibody blocking; multiple orthogonal methods in single study","pmids":["12486241"],"is_preprint":false},{"year":2002,"finding":"CD160 acts as a co-receptor in TCR signal transduction on CD28-negative cytotoxic effector CD8+ T cells. Anti-CD160 mAb enhances CD3-induced proliferation, and CD160 co-precipitates with protein tyrosine kinase p56lck and tyrosine-phosphorylated zeta chains upon TCR-CD3 activation.","method":"Anti-CD160 mAb stimulation, proliferation assays, co-immunoprecipitation (CD160 with p56lck and phospho-zeta chains)","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating p56lck association plus functional proliferation assay; single lab, two orthogonal methods","pmids":["11978774"],"is_preprint":false},{"year":2007,"finding":"CD160-mediated NK cell effector functions (cytotoxicity and cytokine production: IFN-γ, TNF-α, IL-6) require phosphatidylinositol 3-kinase (PI3K) signaling. CD160 engagement induces PI3K polarization and co-localization with CD160, Akt phosphorylation, and ERK phosphorylation. Syk kinase acts upstream of PI3K in this cascade. PI3K inhibitors abrogate both CD160-mediated cytotoxicity and cytokine release; MEK inhibitors block cytokine release; Syk inhibitors block cytokine release.","method":"Confocal microscopy, pharmacological inhibitors of PI3K/MEK/Syk, Western blotting (phospho-Akt), freshly isolated human NK cells","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple pharmacological inhibitors targeting different nodes of the pathway combined with confocal co-localization and Western blot phosphorylation assays; multiple orthogonal methods establishing PI3K-Syk-ERK-Akt cascade","pmids":["17307798"],"is_preprint":false},{"year":2008,"finding":"CD160 inhibits human CD4+ T cell activation through interaction with HVEM (herpesvirus entry mediator). Crosslinking CD160 strongly inhibits CD3/CD28-mediated activation. HVEM CRD1 (cysteine-rich domain 1) is required for CD160 binding; deletion of CRD1 abolishes CD160 and BTLA binding but not LIGHT binding, converting HVEM into a dominant costimulatory molecule. Inhibition of CD4+ T cell activation by HVEM-transfected cells is dependent on both CD160 and BTLA.","method":"Monoclonal antibody crosslinking, T cell activation assays, HVEM deletion mutants (CRD1 deletion), HVEM-transfected cell co-culture, cytokine/proliferation readouts","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of HVEM CRD1 domain combined with functional T cell activation assays; multiple orthogonal approaches establishing coinhibitory mechanism; published in high-impact journal","pmids":["18193050"],"is_preprint":false},{"year":2009,"finding":"CD160 has a transmembrane isoform (CD160-TM) generated by alternative splicing. CD160-TM surface expression is highly restricted to NK cells and is activation-dependent. The CD160-TM cytoplasmic tail is sufficient to mediate ERK1/2 signaling, and initiation of this activation is dependent on the Src-family kinase p56lck. CD160-TM engagement increases CD107a mobilization (degranulation marker).","method":"Alternative splicing characterization by RT-PCR, flow cytometry, NK cell activation assays (CD107a mobilization), Src kinase inhibitor experiments, ERK1/2 signaling readouts","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — identification of novel isoform with functional characterization of cytoplasmic tail signaling via p56lck; single lab with multiple complementary methods","pmids":["19109136"],"is_preprint":false},{"year":2010,"finding":"CD160 signaling in CLL cells activates PI3K-dependent survival and growth signals. CD160 activation protects CLL cells from spontaneous apoptosis, upregulates Bcl-2, Bcl-xL, and Mcl-1, reduces mitochondrial membrane potential collapse and cytochrome c release, induces DNA synthesis and proliferation, and stimulates secretion of IL-6 and IL-8. PI3K inhibitors suppress these survival and activation signals in a dose-dependent manner.","method":"In vitro CLL cell culture with CD160 stimulation, cell viability assays, Western blotting (Bcl-2 family proteins), mitochondrial membrane potential assays, cytochrome c release assays, DNA synthesis/proliferation assays, ELISA (IL-6, IL-8), PI3K pharmacological inhibitors","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (apoptosis assays, protein expression, proliferation, cytokine secretion, pharmacological PI3K inhibition) demonstrating PI3K-dependent mechanism; single lab but highly rigorous","pmids":["20164468"],"is_preprint":false},{"year":2011,"finding":"CD160 is expressed on endothelial cells of newly formed blood vessels in human colon carcinoma and mouse melanoma, but not on vessels of healthy tissues. Monoclonal antibody CL1-R2 targeting CD160 reduces FGF2-induced neovascularization in rabbit cornea, oxygen-induced retinopathy, and Matrigel plug assays. In tumor-bearing mice, anti-CD160 combined with cyclophosphamide caused tumor vasculature regression and normalization of remaining vessels.","method":"Immunohistochemistry, in vivo models (rabbit cornea, retinopathy, Matrigel plug, B16 melanoma), Doppler ultrasonography, intravital microscopy, histology","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo models with functional anti-CD160 antibody; single lab but replicated across several model systems","pmids":["21482699"],"is_preprint":false},{"year":2012,"finding":"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a functionally exhausted subset. Blocking CD160/HVEM interaction increased HIV-specific CD8 T cell proliferation and cytokine production. Transcriptional profiling showed CD160+PD-1+ T cells have downregulation of the NFκB transcriptional node and upregulation of inhibitors of T cell survival and function.","method":"Flow cytometry phenotyping, HVEM-blocking antibody functional assays (proliferation, cytokine production), transcriptional profiling","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blocking of CD160/HVEM with proliferation and cytokine functional readouts plus transcriptomics; single lab with multiple orthogonal methods","pmids":["22916009"],"is_preprint":false},{"year":2013,"finding":"HVEM activates CD160 on effector NK cells to enhance inflammatory cytokine production and cytolysis. Human CD56dim NK cells are costimulated specifically by HVEM but not by other receptors sharing HVEM ligands (LIGHT, LTα, BTLA). Tumor cell-expressed HVEM activates CD160 in NK cells, causing rapid hyperphosphorylation of ERK1/2 and AKT and enhanced target cell cytolysis. In contrast, HVEM activation of BTLA reduces cytolysis.","method":"Human NK cell activation assays, cytokine ELISA (IFN-γ, TNF-α), Western blotting (phospho-ERK1/2, phospho-AKT), cytotoxicity assays, NK cell line experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct signaling readouts (phospho-Western) combined with cytokine and cytotoxicity functional assays; contrasted with BTLA as negative control; multiple orthogonal methods","pmids":["23761635"],"is_preprint":false},{"year":2014,"finding":"CD160-associated CD8 T cell functional impairment (reduced proliferation and perforin expression) is independent of PD-1 expression. Blockade of CD160/CD160-ligand interaction restores CD8 T cell proliferation capacity in a manner that correlates with the proportion of CD160+ CD8 T cells, indicating CD160 negatively regulates TCR-mediated signaling. CD160 expression was not upregulated upon T cell activation or proliferation, unlike PD-1.","method":"Flow cytometry, anti-CD160 blocking antibody, proliferation assays, perforin expression analysis, virus-specific CD8 T cell functional assays (influenza, EBV, CMV)","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blocking with functional proliferation readout; correlative analysis between CD160 frequency and restoration magnitude; single lab","pmids":["25255144"],"is_preprint":false},{"year":2014,"finding":"Both CD160 isoforms (CD160-GPI and CD160-TM) are expressed in human primary CD4+ and CD8+ T cells and are recognized by HVEM ligand, though binding is less pronounced with CD160-TM. HVEM-specific antibodies block HVEM binding to CD160-GPI but enhance HVEM binding to CD160-TM (suggesting antibody-mediated HVEM multimerization or conformational changes facilitate CD160-TM binding). Triggering CD160-GPI on Jurkat cells with bead-bound HVEM-Fc or anti-CD160 mAb enhances cell activation (positive costimulatory role). CD160-GPI-specific antibodies combined with PD-1 blockade synergistically enhance HIV-specific CD8+ T cell proliferation.","method":"Quantitative RT-PCR, flow cytometry, Time-Resolved Fluorescence binding assay, Jurkat cell activation assays, ex vivo PBMC stimulation with HIV antigens, antibody blocking experiments","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assay demonstrating differential isoform-HVEM interaction, combined with functional activation assays; single lab with multiple methods","pmids":["25179432"],"is_preprint":false},{"year":2015,"finding":"CD160 is essential for NK cell IFN-γ production but not cytotoxicity. CD160-deficient mice show severely compromised control of NK-sensitive tumors due to markedly reduced IFN-γ secretion by NK cells (not impaired cytotoxicity). A soluble CD160-Ig fusion protein impairs tumor control and IFN-γ production. Reciprocal bone marrow transfer identifies the intrinsic role of CD160 on NK cells. Intratumoral transfer of CD160+ NK fraction into CD160-/- tumor-bearing mice causes tumor regression.","method":"CD160 knockout mouse generation, tumor challenge assays, IFN-γ ELISA/intracellular cytokine staining, cytotoxicity assays, soluble CD160-Ig fusion protein treatment, reciprocal bone marrow transfer, intratumoral cell transfer","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic knockout combined with multiple orthogonal approaches (bone marrow chimera, soluble decoy, adoptive transfer); clear mechanistic separation of IFN-γ production from cytotoxicity","pmids":["25711213"],"is_preprint":false},{"year":2018,"finding":"CD160 provides costimulatory signals to CD8+ T cells required for optimal effector functions during oral Listeria monocytogenes infection. CD160-/- mice fail to clear oral L. monocytogenes efficiently; this defect is attributable to compromised CD8+ T cells and intraepithelial lymphocytes (not NK cells). CD160-/- CD8+ T cells show reduced granzyme B expression and IFN-γ/TNF-α co-production. Adoptive transfer of CD160-/- CD8+ T cells into RAG-/- recipients results in higher mortality, weight loss, and bacterial burden compared to WT CD8+ T cells.","method":"CD160 knockout mice, in vivo infection model, flow cytometry (granzyme B, IFN-γ, TNF-α), RAG-/- reconstitution experiments, adoptive transfer","journal":"ImmunoHorizons","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple in vivo functional readouts (cytokine, cytotoxic molecule expression, bacterial burden, survival) and adoptive transfer confirming cell-intrinsic role of CD160 on CD8+ T cells","pmids":["31022694"],"is_preprint":false},{"year":2019,"finding":"CD160 serves as a co-inhibitory receptor on NKT cells that dampens cytokine production during early innate immune activation. CD160-/- mice develop severe liver injury after α-galactosylceramide or Concanavalin A challenge, with hyperactivation of NKT cells, elevated AST/ALT, and enhanced IFN-γ, TNF, and IL-4 production. Mixed bone marrow chimeras show this is NKT cell-intrinsic. CD160 and BTLA serve as non-overlapping negative regulators of NKT cells (anti-BTLA mAb aggravates injury in CD160-/- mice).","method":"CD160 knockout mice, mixed bone marrow chimeras, in vivo α-GalCer and ConA challenge, serum ALT/AST measurement, intracellular cytokine staining, anti-BTLA antibody treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with mixed bone marrow chimera (establishing cell-intrinsic role) plus multiple in vivo functional readouts and pharmacological dissection of CD160 vs BTLA pathways","pmids":["31332204"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the human CD160 extracellular domain and its complex with human HVEM was determined. CD160 adopts a unique variation of the immunoglobulin fold and exists as a monomer in solution. The CD160:HVEM assembly shows 1:1 stoichiometry with a binding interface similar to the BTLA:HVEM complex, revealing the chemical and physical determinants of CD160-HVEM recognition.","method":"X-ray crystallography (crystal structure of CD160 alone and CD160:HVEM complex)","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure at atomic resolution defining the binding interface and stoichiometry; directly reveals mechanism of HVEM engagement","pmids":["31230945"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of HVEM revealed distinct surfaces that engage LIGHT (TNF ligand) versus BTLA/CD160 (Ig superfamily ligands), including a human HVEM-LIGHT-CD160 ternary complex showing HVEM can interact simultaneously with both LIGHT and CD160. HVEM knockin mutants that selectively recognize either TNF or Ig ligands in mice demonstrate selective functions: LIGHT binding mediates bacterial clearance in the intestine; Ig ligand (BTLA/CD160) binding ameliorates liver inflammation.","method":"X-ray crystallography (HVEM alone, HVEM-LIGHT, HVEM-CD160, ternary complex), generation of HVEM knockin mutant mice, in vivo infection/inflammation models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures defining distinct binding surfaces combined with knockin mouse models demonstrating selective in vivo functions; multiple orthogonal approaches in single rigorous study","pmids":["34709351"],"is_preprint":false},{"year":2006,"finding":"CD160 does not independently induce cytotoxicity but costimulates CD3-redirected killing in 2B4+CD160+ CD8+ T cells. The 2B4+CD160+ subset expresses high amounts of perforin and granzyme B, and CD160 expression increases from naive to terminally differentiated phenotype during CTL ontogeny.","method":"Flow cytometry, intracellular perforin/granzyme B staining, CD3-redirected cytotoxicity assays with anti-CD160 mAb, phenotypic analysis of CTL subsets","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay showing CD160 costimulates (but does not independently trigger) cytotoxicity; single lab with flow cytometry and cytotoxicity assays","pmids":["16917959"],"is_preprint":false},{"year":2007,"finding":"CD160 acts as a co-activator receptor for CD3-induced proliferation of CD4+CD160+ T cells isolated from inflammatory skin lesions. A novel CD4+CD160+ T cell subset was identified infiltrating inflammatory skin lesions (atopic dermatitis, contact dermatitis, psoriasis). CD160 transcripts can be induced in IL-2 or IL-15-activated CD4+ peripheral blood lymphocytes.","method":"Immunohistochemistry, CD3-induced proliferation assays with anti-CD160 mAb costimulation, RT-PCR, flow cytometry","journal":"The Journal of investigative dermatology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-activation assay in a minor T cell subset from skin lesions; limited mechanistic depth","pmids":["17218942"],"is_preprint":false},{"year":2018,"finding":"TGFβ1 interferes with IFN-γ production by CD160+ NK cells; blocking TGFβ1 restores IFN-γ production specifically in CD160+ NK cells to normal levels. Transcriptomic analysis of sorted CD160+ and CD160- NK cells revealed that CD160+ NK cells have functional activation and high IFN-γ production programs.","method":"Flow cytometry sorting of CD160+ and CD160- NK cells, gene set enrichment analysis/microarray, TGFβ1 blocking antibody, IFN-γ ELISA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sorted primary human NK cells with transcriptomic profiling plus TGFβ1 blockade functional rescue; single lab with orthogonal methods","pmids":["30232222"],"is_preprint":false}],"current_model":"CD160 is a GPI-anchored (and alternatively spliced transmembrane) Ig-superfamily receptor expressed on cytotoxic NK cells, CD8+ T cell subsets, and intraepithelial lymphocytes that engages MHC class I molecules (HLA-C) and HVEM as ligands: on NK cells, MHC-I/HLA-C engagement triggers cytotoxicity and cytokine (IFN-γ, TNF-α, IL-6) production through a PI3K–Syk–AKT–ERK signaling cascade (with CD160-TM signaling additionally through p56lck), whereas on CD4+ and CD8+ T cells, HVEM engagement via CD160 delivers a coinhibitory signal that dampens TCR-mediated activation; the crystal structure of the CD160–HVEM complex reveals a 1:1 stoichiometry at the CRD1 surface of HVEM distinct from the LIGHT binding site, and HVEM can simultaneously engage CD160 and LIGHT in a ternary complex, enabling bidirectional regulation of immune responses."},"narrative":{"mechanistic_narrative":"CD160 is an immunoglobulin-superfamily receptor expressed on cytotoxic NK cells (CD56dim/CD16+), CD8+CD28- T cell subsets, and intestinal intraepithelial lymphocytes that delivers context-dependent activating or inhibitory signals to control lymphocyte effector function [PMID:9743336]. It was originally characterized as a cysteine-rich, GPI-anchored protein forming tightly disulfide-linked multimers [PMID:9743336], with a later-discovered alternatively spliced transmembrane isoform (CD160-TM) restricted to activated NK cells [PMID:19109136]. On NK cells, CD160 engages MHC class I (HLA-C) and HVEM to trigger cytotoxicity and inflammatory cytokine production through a Syk–PI3K–AKT–ERK signaling cascade, with the CD160-TM cytoplasmic tail signaling via the Src-family kinase p56lck [PMID:12486241, PMID:17307798, PMID:19109136, PMID:23761635]; this pathway is selectively required for NK-cell IFN-γ production rather than cytotoxicity, as shown in CD160-deficient mice that lose control of NK-sensitive tumors [PMID:25711213]. The same PI3K-dependent survival program is co-opted in chronic lymphocytic leukemia cells, where CD160 activation upregulates Bcl-2/Bcl-xL/Mcl-1 and protects against apoptosis [PMID:20164468]. On T cells and NKT cells, CD160 engagement of HVEM at its CRD1 surface delivers a coinhibitory signal that dampens TCR-driven activation and innate cytokine output [PMID:18193050, PMID:31332204], while the receptor also acts as a costimulator of TCR-redirected killing in differentiated CD8+ effector cells [PMID:11978774, PMID:16917959]. Crystallography established that CD160 is a monomeric Ig fold binding HVEM in a 1:1 complex distinct from the LIGHT-binding site, and that HVEM can simultaneously engage LIGHT and CD160 in a ternary complex, providing the structural basis for bidirectional immune regulation [PMID:31230945, PMID:34709351]. CD160 is additionally expressed selectively on tumor-associated neovascular endothelium, where antibody targeting causes regression of tumor vasculature [PMID:21482699].","teleology":[{"year":1998,"claim":"Established CD160 as a distinct molecular entity by cloning it and showing it is a GPI-anchored, multimeric cysteine-rich Ig-like protein with lymphocyte-restricted expression.","evidence":"cDNA cloning, reducing/non-reducing immunoprecipitation, RNA blot, and flow cytometry on NK and T cell subsets","pmids":["9743336"],"confidence":"High","gaps":["No ligand or signaling function defined at this stage","Multimerization stoichiometry of the native receptor not resolved"]},{"year":2002,"claim":"Identified MHC class I (HLA-C) as a CD160 ligand whose engagement triggers NK cytolysis, defining CD160 as a functional activating receptor.","evidence":"Recombinant soluble HLA-Cw3/CD160 binding plus antibody-blocking cytotoxicity assays","pmids":["12486241"],"confidence":"High","gaps":["Downstream signaling cascade not yet mapped","Affinity and physiological relevance of HLA-C binding versus other ligands not quantified"]},{"year":2002,"claim":"Showed CD160 functions as a TCR co-receptor on CD28-negative CD8+ effector T cells, physically linking it to proximal TCR signaling machinery.","evidence":"Anti-CD160 proliferation assays and co-immunoprecipitation with p56lck and phospho-zeta chains","pmids":["11978774"],"confidence":"Medium","gaps":["GPI-anchored isoform lacks a cytoplasmic tail, leaving the mechanism of p56lck coupling unexplained","Single-lab co-IP without reciprocal validation"]},{"year":2007,"claim":"Defined the NK-cell signaling cascade downstream of CD160 as Syk→PI3K→AKT/ERK, explaining how engagement drives both cytotoxicity and cytokine release.","evidence":"Pharmacological inhibitors of PI3K/MEK/Syk, confocal co-localization, and phospho-Western blotting in primary human NK cells","pmids":["17307798"],"confidence":"High","gaps":["How a GPI-anchored receptor recruits Syk/PI3K not resolved","Inhibitor specificity caveats for the kinase assignments"]},{"year":2008,"claim":"Identified HVEM as a second CD160 ligand and reversed the functional picture by showing CD160-HVEM engagement coinhibits T cell activation via the HVEM CRD1 domain.","evidence":"HVEM CRD1 deletion mutagenesis with T cell activation/cytokine assays and HVEM-transfected co-culture","pmids":["18193050"],"confidence":"High","gaps":["Relative contributions of CD160 versus BTLA at shared CRD1 surface not separated","Inhibitory signaling output of CD160 not mechanistically traced"]},{"year":2009,"claim":"Discovered the transmembrane isoform CD160-TM and showed its cytoplasmic tail is sufficient for p56lck-dependent ERK signaling and NK degranulation, providing a signaling-competent form of the receptor.","evidence":"RT-PCR isoform characterization, Src-kinase inhibitor experiments, CD107a mobilization assays","pmids":["19109136"],"confidence":"Medium","gaps":["Relative physiological abundance of TM versus GPI isoform unclear","Direct kinase-tail interaction not biochemically demonstrated"]},{"year":2010,"claim":"Demonstrated that CD160-PI3K signaling drives a pro-survival program in CLL cells, extending the activating cascade to a pathological context.","evidence":"CLL cell culture with CD160 stimulation, Bcl-2 family Westerns, apoptosis/proliferation assays, PI3K inhibition","pmids":["20164468"],"confidence":"High","gaps":["Ligand driving CD160 activation in CLL not identified","Connection to the NK Syk–PI3K cascade not formally established"]},{"year":2013,"claim":"Established that HVEM, not other shared ligands, costimulates CD160 on NK cells to enhance cytolysis and cytokine output, contrasting with HVEM-BTLA inhibition.","evidence":"NK activation assays, phospho-ERK/AKT Westerns, cytotoxicity and cytokine ELISAs with BTLA as comparator","pmids":["23761635"],"confidence":"High","gaps":["How identical HVEM engagement yields opposite outcomes on NK (activating) versus T cells (inhibitory) not resolved"]},{"year":2012,"claim":"Linked CD160 to T cell exhaustion, showing CD160/PD-1 co-expression marks dysfunctional HIV-specific CD8 T cells and that CD160/HVEM blockade restores function.","evidence":"Flow phenotyping, HVEM-blocking functional assays, transcriptional profiling of exhausted T cells","pmids":["22916009"],"confidence":"Medium","gaps":["Whether CD160 acts via HVEM exclusively in exhaustion not isolated","Correlation versus causation in the exhaustion signature"]},{"year":2014,"claim":"Resolved that CD160-mediated CD8 T cell suppression operates independently of PD-1 and is not activation-induced, distinguishing it from the canonical exhaustion checkpoint.","evidence":"Anti-CD160 blocking with proliferation/perforin readouts across influenza/EBV/CMV-specific T cells","pmids":["25255144"],"confidence":"Medium","gaps":["The CD160 ligand operative in these settings not pinned down","Correlative restoration data"]},{"year":2014,"claim":"Showed both CD160 isoforms bind HVEM with differing efficiency and that CD160-GPI triggering can deliver a positive costimulatory signal, underscoring the receptor's bidirectional output.","evidence":"Time-resolved fluorescence binding, Jurkat activation assays, antibody-blocking and HIV-antigen PBMC stimulation","pmids":["25179432"],"confidence":"Medium","gaps":["Molecular basis for isoform-dependent HVEM binding differences unresolved","Single-lab functional assays"]},{"year":2015,"claim":"Used genetic knockout to dissociate CD160 functions, proving it is intrinsically required for NK-cell IFN-γ production but dispensable for cytotoxicity in tumor control.","evidence":"CD160-/- mice, tumor challenge, bone marrow chimeras, soluble CD160-Ig decoy, intratumoral NK transfer","pmids":["25711213"],"confidence":"High","gaps":["Ligand driving the in vivo NK IFN-γ response not defined","Reconciliation with earlier reports of CD160-driven cytotoxicity"]},{"year":2018,"claim":"Demonstrated a cell-intrinsic costimulatory role for CD160 on CD8 T cells and IELs during oral Listeria infection, revealing a protective effector function in vivo.","evidence":"CD160-/- infection model, granzyme B/IFN-γ/TNF flow cytometry, RAG-/- adoptive transfer","pmids":["31022694"],"confidence":"High","gaps":["Costimulatory versus coinhibitory role context-dependence not mechanistically explained","Ligand engaged during mucosal infection unidentified"]},{"year":2019,"claim":"Established CD160 as a non-redundant coinhibitory receptor on NKT cells that limits innate cytokine-driven liver injury, parallel to but distinct from BTLA.","evidence":"CD160-/- mice, mixed bone marrow chimeras, α-GalCer/ConA challenge, anti-BTLA dissection","pmids":["31332204"],"confidence":"High","gaps":["Inhibitory signaling mechanism in NKT cells not traced","How CD160 and BTLA divide labor at shared HVEM not resolved"]},{"year":2019,"claim":"Provided the atomic-level basis for CD160-HVEM recognition, showing CD160 is a monomeric Ig fold binding HVEM 1:1 at an interface resembling BTLA:HVEM.","evidence":"X-ray crystallography of CD160 alone and the CD160:HVEM complex","pmids":["31230945"],"confidence":"High","gaps":["Reconciliation of monomeric solution behavior with earlier disulfide-multimer biochemistry","Structure does not explain divergent signaling outputs"]},{"year":2021,"claim":"Defined how HVEM coordinates competing ligands, showing distinct surfaces for LIGHT versus CD160/BTLA, a ternary LIGHT-HVEM-CD160 complex, and selective in vivo functions of each axis.","evidence":"Crystal structures (HVEM, HVEM-LIGHT, HVEM-CD160, ternary) plus HVEM ligand-selective knockin mice in infection/inflammation models","pmids":["34709351"],"confidence":"High","gaps":["Functional consequence of simultaneous LIGHT/CD160 occupancy on the same HVEM not directly tested","Whether ternary complex forms physiologically in tissue"]},{"year":2018,"claim":"Linked CD160+ NK cells to a high-IFN-γ functional program suppressed by TGFβ1, identifying a microenvironmental brake on CD160-driven NK activation.","evidence":"Sorted CD160+/- NK transcriptomics, GSEA, and TGFβ1-blocking IFN-γ rescue","pmids":["30232222"],"confidence":"Medium","gaps":["Mechanism of TGFβ1 interference with CD160 signaling not defined","Correlative transcriptomics"]},{"year":2011,"claim":"Revealed a non-lymphocyte role for CD160 as a marker of tumor neovascular endothelium and a therapeutic anti-angiogenic target.","evidence":"Immunohistochemistry and anti-CD160 antibody across rabbit cornea, retinopathy, Matrigel, and melanoma models","pmids":["21482699"],"confidence":"Medium","gaps":["Endothelial CD160 ligand and signaling mechanism unknown","Relationship to lymphocyte CD160 function unclear"]},{"year":null,"claim":"It remains unresolved how a single receptor delivers opposite (activating versus inhibitory) signals depending on cell type and ligand, and how GPI-anchored CD160 lacking a cytoplasmic tail couples to intracellular kinases.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural or biochemical mechanism for GPI-isoform signal transduction","No unified model reconciling costimulatory and coinhibitory outcomes","Ligand(s) governing each functional context not fully mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,4,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,14,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,4,9,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,9,6]}],"complexes":[],"partners":["HVEM","HLA-C","LCK","LIGHT","BTLA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95971","full_name":"CD160 antigen","aliases":["Natural killer cell receptor BY55"],"length_aa":181,"mass_kda":19.8,"function":"Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells (PubMed:11978774, PubMed:17307798, PubMed:19109136). Receptor for both classical and non-classical MHC class I molecules (PubMed:12486241, PubMed:9973372). In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response (PubMed:12486241). On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells (PubMed:9973372). Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion (PubMed:25255144). On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites (PubMed:16809620). Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (By similarity). On activated CD4+ T cells, interacts with TNFRSF14 and down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity) The soluble GPI-cleaved form, usually released by activated lymphocytes, might play an immune regulatory role by limiting lymphocyte effector functions","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95971/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD160","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD160","total_profiled":1310},"omim":[{"mim_id":"604463","title":"CD160 ANTIGEN; CD160","url":"https://www.omim.org/entry/604463"},{"mim_id":"602746","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14","url":"https://www.omim.org/entry/602746"},{"mim_id":"102582","title":"SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; STAT3","url":"https://www.omim.org/entry/102582"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":4.8},{"tissue":"brain","ntpm":15.2},{"tissue":"intestine","ntpm":4.4},{"tissue":"liver","ntpm":4.7},{"tissue":"lymphoid tissue","ntpm":12.7}],"url":"https://www.proteinatlas.org/search/CD160"},"hgnc":{"alias_symbol":["BY55","NK1","NK28"],"prev_symbol":[]},"alphafold":{"accession":"O95971","domains":[{"cath_id":"2.60.40.10","chopping":"27-140","consensus_level":"high","plddt":90.5021,"start":27,"end":140}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95971","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95971-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95971-F1-predicted_aligned_error_v6.png","plddt_mean":75.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD160","jax_strain_url":"https://www.jax.org/strain/search?query=CD160"},"sequence":{"accession":"O95971","fasta_url":"https://rest.uniprot.org/uniprotkb/O95971.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95971/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95971"}},"corpus_meta":[{"pmid":"9143699","id":"PMC_9143699","title":"Mouse CD1-specific NK1 T cells: development, specificity, and function.","date":"1997","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9143699","citation_count":986,"is_preprint":false},{"pmid":"18193050","id":"PMC_18193050","title":"CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18193050","citation_count":283,"is_preprint":false},{"pmid":"11927628","id":"PMC_11927628","title":"A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11927628","citation_count":282,"is_preprint":false},{"pmid":"7546402","id":"PMC_7546402","title":"Mouse NK1+ T cells.","date":"1995","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7546402","citation_count":256,"is_preprint":false},{"pmid":"9571643","id":"PMC_9571643","title":"The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles.","date":"1998","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/9571643","citation_count":248,"is_preprint":false},{"pmid":"19426226","id":"PMC_19426226","title":"The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426226","citation_count":247,"is_preprint":false},{"pmid":"19830744","id":"PMC_19830744","title":"CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19830744","citation_count":236,"is_preprint":false},{"pmid":"10190898","id":"PMC_10190898","title":"Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10190898","citation_count":232,"is_preprint":false},{"pmid":"10671176","id":"PMC_10671176","title":"Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists.","date":"1999","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10671176","citation_count":222,"is_preprint":false},{"pmid":"9834059","id":"PMC_9834059","title":"Differentiation of human NK cells into NK1 and NK2 subsets.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9834059","citation_count":222,"is_preprint":false},{"pmid":"12562137","id":"PMC_12562137","title":"Neurobiology of substance P and the NK1 receptor.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562137","citation_count":221,"is_preprint":false},{"pmid":"8808053","id":"PMC_8808053","title":"Mouse NK1.1+ T cells: a new family of T cells.","date":"1996","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/8808053","citation_count":213,"is_preprint":false},{"pmid":"7545030","id":"PMC_7545030","title":"Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor.","date":"1995","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/7545030","citation_count":196,"is_preprint":false},{"pmid":"10443564","id":"PMC_10443564","title":"The tachykinin NK1 receptor in the brain: pharmacology and putative functions.","date":"1999","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10443564","citation_count":176,"is_preprint":false},{"pmid":"9574822","id":"PMC_9574822","title":"The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.","date":"1997","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/9574822","citation_count":174,"is_preprint":false},{"pmid":"26421291","id":"PMC_26421291","title":"Biological and Pharmacological Aspects of the NK1-Receptor.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26421291","citation_count":162,"is_preprint":false},{"pmid":"24705689","id":"PMC_24705689","title":"Involvement of substance P and the NK-1 receptor in human pathology.","date":"2014","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/24705689","citation_count":158,"is_preprint":false},{"pmid":"20007250","id":"PMC_20007250","title":"HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20007250","citation_count":133,"is_preprint":false},{"pmid":"17923504","id":"PMC_17923504","title":"Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17923504","citation_count":131,"is_preprint":false},{"pmid":"22916009","id":"PMC_22916009","title":"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22916009","citation_count":124,"is_preprint":false},{"pmid":"15964684","id":"PMC_15964684","title":"Role of NK-1 neurotransmission in opioid-induced hyperalgesia.","date":"2005","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/15964684","citation_count":122,"is_preprint":false},{"pmid":"23933301","id":"PMC_23933301","title":"Involvement of substance P and the NK-1 receptor in cancer progression.","date":"2013","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/23933301","citation_count":119,"is_preprint":false},{"pmid":"9743336","id":"PMC_9743336","title":"Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9743336","citation_count":114,"is_preprint":false},{"pmid":"12562139","id":"PMC_12562139","title":"Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562139","citation_count":114,"is_preprint":false},{"pmid":"16751398","id":"PMC_16751398","title":"Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16751398","citation_count":110,"is_preprint":false},{"pmid":"12486241","id":"PMC_12486241","title":"Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12486241","citation_count":109,"is_preprint":false},{"pmid":"25711213","id":"PMC_25711213","title":"CD160 is essential for NK-mediated IFN-γ production.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25711213","citation_count":95,"is_preprint":false},{"pmid":"12620925","id":"PMC_12620925","title":"Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS.","date":"2003","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12620925","citation_count":88,"is_preprint":false},{"pmid":"16547241","id":"PMC_16547241","title":"Long-term retention of mature NK1.1+ NKT cells in the thymus.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547241","citation_count":87,"is_preprint":false},{"pmid":"9164926","id":"PMC_9164926","title":"NK1.1+ CD4+ T cells lose NK1.1 expression upon in vitro activation.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9164926","citation_count":77,"is_preprint":false},{"pmid":"23761635","id":"PMC_23761635","title":"CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23761635","citation_count":75,"is_preprint":false},{"pmid":"21226668","id":"PMC_21226668","title":"The NK-1 receptor: a new target in cancer therapy.","date":"2011","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21226668","citation_count":73,"is_preprint":false},{"pmid":"11805341","id":"PMC_11805341","title":"The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11805341","citation_count":71,"is_preprint":false},{"pmid":"25255144","id":"PMC_25255144","title":"CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/25255144","citation_count":68,"is_preprint":false},{"pmid":"21324341","id":"PMC_21324341","title":"CD160: a unique activating NK cell receptor.","date":"2011","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/21324341","citation_count":66,"is_preprint":false},{"pmid":"15892660","id":"PMC_15892660","title":"Do substance P and the NK1 receptor have a role in depression and anxiety?","date":"2005","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15892660","citation_count":66,"is_preprint":false},{"pmid":"11179779","id":"PMC_11179779","title":"Localization of NK1 and NK3 receptors in guinea-pig brain.","date":"2001","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/11179779","citation_count":60,"is_preprint":false},{"pmid":"14640927","id":"PMC_14640927","title":"Aprepitant--a novel NK1-receptor antagonist.","date":"2003","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/14640927","citation_count":56,"is_preprint":false},{"pmid":"11978774","id":"PMC_11978774","title":"BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11978774","citation_count":55,"is_preprint":false},{"pmid":"11157089","id":"PMC_11157089","title":"The NK1 receptor is essential for the full expression of noxious inhibitory controls in the mouse.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11157089","citation_count":53,"is_preprint":false},{"pmid":"10954033","id":"PMC_10954033","title":"The role of tachykinins via NK1 receptors in progression of human gliomas.","date":"2000","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10954033","citation_count":51,"is_preprint":false},{"pmid":"12562140","id":"PMC_12562140","title":"Clinical experience with substance P receptor (NK1) antagonists in depression.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562140","citation_count":50,"is_preprint":false},{"pmid":"19109136","id":"PMC_19109136","title":"Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19109136","citation_count":49,"is_preprint":false},{"pmid":"8090781","id":"PMC_8090781","title":"BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8090781","citation_count":48,"is_preprint":false},{"pmid":"12562138","id":"PMC_12562138","title":"Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1).","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562138","citation_count":48,"is_preprint":false},{"pmid":"16155744","id":"PMC_16155744","title":"Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain.","date":"2005","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/16155744","citation_count":48,"is_preprint":false},{"pmid":"30232222","id":"PMC_30232222","title":"Reduced CD160 Expression Contributes to Impaired NK-cell Function and Poor Clinical Outcomes in Patients with HCC.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30232222","citation_count":47,"is_preprint":false},{"pmid":"8717372","id":"PMC_8717372","title":"Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse.","date":"1996","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8717372","citation_count":47,"is_preprint":false},{"pmid":"12492418","id":"PMC_12492418","title":"The murine neurokinin NK1 receptor gene contributes to the adult hypoxic facilitation of ventilation.","date":"2002","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12492418","citation_count":46,"is_preprint":false},{"pmid":"25228541","id":"PMC_25228541","title":"NK1 receptor antagonists as a new treatment for corneal neovascularization.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/25228541","citation_count":44,"is_preprint":false},{"pmid":"12056558","id":"PMC_12056558","title":"New insights into the antidepressant actions of substance P (NK1 receptor) antagonists.","date":"2002","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12056558","citation_count":44,"is_preprint":false},{"pmid":"33931471","id":"PMC_33931471","title":"Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33931471","citation_count":42,"is_preprint":false},{"pmid":"20164468","id":"PMC_20164468","title":"CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20164468","citation_count":42,"is_preprint":false},{"pmid":"12020057","id":"PMC_12020057","title":"Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.","date":"2002","source":"Current opinion in investigational drugs (London, England : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/12020057","citation_count":42,"is_preprint":false},{"pmid":"25861784","id":"PMC_25861784","title":"NK-1 Antagonists and Itch.","date":"2015","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25861784","citation_count":41,"is_preprint":false},{"pmid":"16917959","id":"PMC_16917959","title":"The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16917959","citation_count":41,"is_preprint":false},{"pmid":"24605029","id":"PMC_24605029","title":"Involvement of substance P and the NK-1 receptor in pancreatic cancer.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24605029","citation_count":40,"is_preprint":false},{"pmid":"16764942","id":"PMC_16764942","title":"Characterization of murine CD160+ CD8+ T lymphocytes.","date":"2006","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16764942","citation_count":40,"is_preprint":false},{"pmid":"23303056","id":"PMC_23303056","title":"The NK1 receptor antagonist L822429 reduces heroin reinforcement.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23303056","citation_count":39,"is_preprint":false},{"pmid":"21715317","id":"PMC_21715317","title":"Differential and tumor-specific expression of CD160 in B-cell malignancies.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21715317","citation_count":38,"is_preprint":false},{"pmid":"17895403","id":"PMC_17895403","title":"Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17895403","citation_count":37,"is_preprint":false},{"pmid":"34347289","id":"PMC_34347289","title":"Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34347289","citation_count":36,"is_preprint":false},{"pmid":"24969614","id":"PMC_24969614","title":"Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.","date":"2014","source":"Experimental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24969614","citation_count":36,"is_preprint":false},{"pmid":"21482699","id":"PMC_21482699","title":"A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21482699","citation_count":36,"is_preprint":false},{"pmid":"31230945","id":"PMC_31230945","title":"Structural Basis of CD160:HVEM Recognition.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31230945","citation_count":35,"is_preprint":false},{"pmid":"7819527","id":"PMC_7819527","title":"NK1 receptor expression by cholinergic interneurones in human striatum.","date":"1994","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/7819527","citation_count":34,"is_preprint":false},{"pmid":"18954559","id":"PMC_18954559","title":"17beta-estradiol suppresses cytotoxicity and proliferative capacity of murine splenic NK1.1+ cells.","date":"2008","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18954559","citation_count":34,"is_preprint":false},{"pmid":"31190215","id":"PMC_31190215","title":"NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.","date":"2019","source":"Dermatology and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31190215","citation_count":33,"is_preprint":false},{"pmid":"28753469","id":"PMC_28753469","title":"NK1 receptor antagonists for depression: Why a validated concept was abandoned.","date":"2017","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/28753469","citation_count":32,"is_preprint":false},{"pmid":"31332204","id":"PMC_31332204","title":"CD160 serves as a negative regulator of NKT cells in acute hepatic injury.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31332204","citation_count":32,"is_preprint":false},{"pmid":"25883386","id":"PMC_25883386","title":"Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.","date":"2015","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25883386","citation_count":32,"is_preprint":false},{"pmid":"30538204","id":"PMC_30538204","title":"Crystal structure of the human NK1 tachykinin receptor.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30538204","citation_count":32,"is_preprint":false},{"pmid":"31480582","id":"PMC_31480582","title":"The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.","date":"2019","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/31480582","citation_count":31,"is_preprint":false},{"pmid":"19369645","id":"PMC_19369645","title":"Murine endometrial and decidual NK1.1+ natural killer cells display a B220+CD11c+ cell surface phenotype.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19369645","citation_count":31,"is_preprint":false},{"pmid":"7517328","id":"PMC_7517328","title":"Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems.","date":"1994","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7517328","citation_count":31,"is_preprint":false},{"pmid":"17307798","id":"PMC_17307798","title":"CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.","date":"2007","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17307798","citation_count":30,"is_preprint":false},{"pmid":"31022694","id":"PMC_31022694","title":"CD160 Stimulates CD8+ T Cell Responses and Is Required for Optimal Protective Immunity to Listeria monocytogenes.","date":"2018","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/31022694","citation_count":30,"is_preprint":false},{"pmid":"11071316","id":"PMC_11071316","title":"Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain.","date":"2000","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11071316","citation_count":29,"is_preprint":false},{"pmid":"11864635","id":"PMC_11864635","title":"The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal.","date":"2002","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11864635","citation_count":28,"is_preprint":false},{"pmid":"36793857","id":"PMC_36793857","title":"TCRαβ+NK1.1-CD4-CD8- double-negative T cells inhibit central and peripheral inflammation and ameliorate ischemic stroke in mice.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/36793857","citation_count":28,"is_preprint":false},{"pmid":"12687689","id":"PMC_12687689","title":"VR1-positive primary afferents contact NK1-positive spinoparabrachial neurons.","date":"2003","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12687689","citation_count":28,"is_preprint":false},{"pmid":"17218942","id":"PMC_17218942","title":"Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17218942","citation_count":28,"is_preprint":false},{"pmid":"16501582","id":"PMC_16501582","title":"[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16501582","citation_count":28,"is_preprint":false},{"pmid":"11950514","id":"PMC_11950514","title":"Neurokinin NK1- and NK3-immunoreactive neurons in serotonergic cell groups in the rat brain.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/11950514","citation_count":28,"is_preprint":false},{"pmid":"30282707","id":"PMC_30282707","title":"Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/30282707","citation_count":27,"is_preprint":false},{"pmid":"9122219","id":"PMC_9122219","title":"Generation of NK1.1+ T cell antigen receptor alpha/beta+ thymocytes associated with intact thymic structure.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9122219","citation_count":27,"is_preprint":false},{"pmid":"31862674","id":"PMC_31862674","title":"Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31862674","citation_count":26,"is_preprint":false},{"pmid":"16634686","id":"PMC_16634686","title":"NK1 receptor antagonists under investigation for the treatment of affective disorders.","date":"2006","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/16634686","citation_count":26,"is_preprint":false},{"pmid":"25179432","id":"PMC_25179432","title":"CD160 isoforms and regulation of CD4 and CD8 T-cell responses.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25179432","citation_count":25,"is_preprint":false},{"pmid":"34709351","id":"PMC_34709351","title":"HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34709351","citation_count":25,"is_preprint":false},{"pmid":"19351798","id":"PMC_19351798","title":"NK1 receptor antagonism and emotional processing in healthy volunteers.","date":"2009","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19351798","citation_count":25,"is_preprint":false},{"pmid":"7694756","id":"PMC_7694756","title":"Identification of both NK1 and NK2 receptors in guinea-pig airways.","date":"1993","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7694756","citation_count":24,"is_preprint":false},{"pmid":"11353005","id":"PMC_11353005","title":"Differential expression of functionally identified and immunohistochemically identified NK(1) receptors on sympathetic neurons.","date":"2001","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/11353005","citation_count":24,"is_preprint":false},{"pmid":"32055919","id":"PMC_32055919","title":"CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer.","date":"2020","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/32055919","citation_count":23,"is_preprint":false},{"pmid":"9030975","id":"PMC_9030975","title":"Functional characterization of NK1.1 + Ly-6C+ cells.","date":"1996","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/9030975","citation_count":23,"is_preprint":false},{"pmid":"30333822","id":"PMC_30333822","title":"iNKT Cells Suppress Pathogenic NK1.1+CD8+ T Cells in DSS-Induced Colitis.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30333822","citation_count":23,"is_preprint":false},{"pmid":"9619484","id":"PMC_9619484","title":"Natural killer cell proliferation induced by anti-NK1.1 and IL-2.","date":"1998","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9619484","citation_count":23,"is_preprint":false},{"pmid":"16167886","id":"PMC_16167886","title":"Differentiation of NK1 and NK2 cells.","date":"2005","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16167886","citation_count":22,"is_preprint":false},{"pmid":"11726770","id":"PMC_11726770","title":"NK1 receptor and the ventral medulla of the rat: bulbospinal and catecholaminergic neurons.","date":"2001","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11726770","citation_count":22,"is_preprint":false},{"pmid":"32565950","id":"PMC_32565950","title":"lncRNA-CD160 decreases the immunity of CD8+ T cells through epigenetic mechanisms in hepatitis B virus infection.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32565950","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47561,"output_tokens":6074,"usd":0.116897,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15093,"output_tokens":5372,"usd":0.104883,"stage2_stop_reason":"end_turn"},"total_usd":0.22178,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"CD160 (BY55) is a GPI-anchored, cysteine-rich protein of 181 amino acids with a single Ig-like domain weakly homologous to killer inhibitory receptors. Reduction and carboxyamidomethylation of immunoprecipitated BY55 gave a 27 kDa band, whereas reduction alone gave 80 kDa, indicating CD160 forms tightly disulfide-linked multimers. Expression is restricted to CD56dim/CD16+ NK cells (high cytolytic activity) but not CD56bright/CD16- NK cells, and to CD8+CD28- T cells and intestinal intraepithelial lymphocytes.\",\n      \"method\": \"cDNA cloning, immunoprecipitation with reducing/non-reducing SDS-PAGE, RNA blot analysis, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — molecular cloning with biochemical characterization (immunoprecipitation, reduction/alkylation) establishing multimeric GPI-anchored structure; replicated across multiple methods in single rigorous study\",\n      \"pmids\": [\"9743336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD160 receptor engagement by HLA-C molecules (constitutively expressed on K562 cells) triggers NK cell cytolytic activity. Direct interaction between recombinant soluble HLA-Cw3 and CD160 proteins was demonstrated. CD158b inhibitory receptors partially interfere with CD160-mediated cytotoxicity, whereas CD94/CD159a and CD85j do not.\",\n      \"method\": \"Monoclonal antibody blocking assays, cytotoxicity assays, recombinant protein binding (soluble HLA-Cw3 and CD160), flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct protein-protein interaction shown with recombinant proteins plus functional cytotoxicity assay with antibody blocking; multiple orthogonal methods in single study\",\n      \"pmids\": [\"12486241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD160 acts as a co-receptor in TCR signal transduction on CD28-negative cytotoxic effector CD8+ T cells. Anti-CD160 mAb enhances CD3-induced proliferation, and CD160 co-precipitates with protein tyrosine kinase p56lck and tyrosine-phosphorylated zeta chains upon TCR-CD3 activation.\",\n      \"method\": \"Anti-CD160 mAb stimulation, proliferation assays, co-immunoprecipitation (CD160 with p56lck and phospho-zeta chains)\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating p56lck association plus functional proliferation assay; single lab, two orthogonal methods\",\n      \"pmids\": [\"11978774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD160-mediated NK cell effector functions (cytotoxicity and cytokine production: IFN-γ, TNF-α, IL-6) require phosphatidylinositol 3-kinase (PI3K) signaling. CD160 engagement induces PI3K polarization and co-localization with CD160, Akt phosphorylation, and ERK phosphorylation. Syk kinase acts upstream of PI3K in this cascade. PI3K inhibitors abrogate both CD160-mediated cytotoxicity and cytokine release; MEK inhibitors block cytokine release; Syk inhibitors block cytokine release.\",\n      \"method\": \"Confocal microscopy, pharmacological inhibitors of PI3K/MEK/Syk, Western blotting (phospho-Akt), freshly isolated human NK cells\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple pharmacological inhibitors targeting different nodes of the pathway combined with confocal co-localization and Western blot phosphorylation assays; multiple orthogonal methods establishing PI3K-Syk-ERK-Akt cascade\",\n      \"pmids\": [\"17307798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD160 inhibits human CD4+ T cell activation through interaction with HVEM (herpesvirus entry mediator). Crosslinking CD160 strongly inhibits CD3/CD28-mediated activation. HVEM CRD1 (cysteine-rich domain 1) is required for CD160 binding; deletion of CRD1 abolishes CD160 and BTLA binding but not LIGHT binding, converting HVEM into a dominant costimulatory molecule. Inhibition of CD4+ T cell activation by HVEM-transfected cells is dependent on both CD160 and BTLA.\",\n      \"method\": \"Monoclonal antibody crosslinking, T cell activation assays, HVEM deletion mutants (CRD1 deletion), HVEM-transfected cell co-culture, cytokine/proliferation readouts\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of HVEM CRD1 domain combined with functional T cell activation assays; multiple orthogonal approaches establishing coinhibitory mechanism; published in high-impact journal\",\n      \"pmids\": [\"18193050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD160 has a transmembrane isoform (CD160-TM) generated by alternative splicing. CD160-TM surface expression is highly restricted to NK cells and is activation-dependent. The CD160-TM cytoplasmic tail is sufficient to mediate ERK1/2 signaling, and initiation of this activation is dependent on the Src-family kinase p56lck. CD160-TM engagement increases CD107a mobilization (degranulation marker).\",\n      \"method\": \"Alternative splicing characterization by RT-PCR, flow cytometry, NK cell activation assays (CD107a mobilization), Src kinase inhibitor experiments, ERK1/2 signaling readouts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — identification of novel isoform with functional characterization of cytoplasmic tail signaling via p56lck; single lab with multiple complementary methods\",\n      \"pmids\": [\"19109136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD160 signaling in CLL cells activates PI3K-dependent survival and growth signals. CD160 activation protects CLL cells from spontaneous apoptosis, upregulates Bcl-2, Bcl-xL, and Mcl-1, reduces mitochondrial membrane potential collapse and cytochrome c release, induces DNA synthesis and proliferation, and stimulates secretion of IL-6 and IL-8. PI3K inhibitors suppress these survival and activation signals in a dose-dependent manner.\",\n      \"method\": \"In vitro CLL cell culture with CD160 stimulation, cell viability assays, Western blotting (Bcl-2 family proteins), mitochondrial membrane potential assays, cytochrome c release assays, DNA synthesis/proliferation assays, ELISA (IL-6, IL-8), PI3K pharmacological inhibitors\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (apoptosis assays, protein expression, proliferation, cytokine secretion, pharmacological PI3K inhibition) demonstrating PI3K-dependent mechanism; single lab but highly rigorous\",\n      \"pmids\": [\"20164468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD160 is expressed on endothelial cells of newly formed blood vessels in human colon carcinoma and mouse melanoma, but not on vessels of healthy tissues. Monoclonal antibody CL1-R2 targeting CD160 reduces FGF2-induced neovascularization in rabbit cornea, oxygen-induced retinopathy, and Matrigel plug assays. In tumor-bearing mice, anti-CD160 combined with cyclophosphamide caused tumor vasculature regression and normalization of remaining vessels.\",\n      \"method\": \"Immunohistochemistry, in vivo models (rabbit cornea, retinopathy, Matrigel plug, B16 melanoma), Doppler ultrasonography, intravital microscopy, histology\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo models with functional anti-CD160 antibody; single lab but replicated across several model systems\",\n      \"pmids\": [\"21482699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a functionally exhausted subset. Blocking CD160/HVEM interaction increased HIV-specific CD8 T cell proliferation and cytokine production. Transcriptional profiling showed CD160+PD-1+ T cells have downregulation of the NFκB transcriptional node and upregulation of inhibitors of T cell survival and function.\",\n      \"method\": \"Flow cytometry phenotyping, HVEM-blocking antibody functional assays (proliferation, cytokine production), transcriptional profiling\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blocking of CD160/HVEM with proliferation and cytokine functional readouts plus transcriptomics; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22916009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HVEM activates CD160 on effector NK cells to enhance inflammatory cytokine production and cytolysis. Human CD56dim NK cells are costimulated specifically by HVEM but not by other receptors sharing HVEM ligands (LIGHT, LTα, BTLA). Tumor cell-expressed HVEM activates CD160 in NK cells, causing rapid hyperphosphorylation of ERK1/2 and AKT and enhanced target cell cytolysis. In contrast, HVEM activation of BTLA reduces cytolysis.\",\n      \"method\": \"Human NK cell activation assays, cytokine ELISA (IFN-γ, TNF-α), Western blotting (phospho-ERK1/2, phospho-AKT), cytotoxicity assays, NK cell line experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct signaling readouts (phospho-Western) combined with cytokine and cytotoxicity functional assays; contrasted with BTLA as negative control; multiple orthogonal methods\",\n      \"pmids\": [\"23761635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD160-associated CD8 T cell functional impairment (reduced proliferation and perforin expression) is independent of PD-1 expression. Blockade of CD160/CD160-ligand interaction restores CD8 T cell proliferation capacity in a manner that correlates with the proportion of CD160+ CD8 T cells, indicating CD160 negatively regulates TCR-mediated signaling. CD160 expression was not upregulated upon T cell activation or proliferation, unlike PD-1.\",\n      \"method\": \"Flow cytometry, anti-CD160 blocking antibody, proliferation assays, perforin expression analysis, virus-specific CD8 T cell functional assays (influenza, EBV, CMV)\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blocking with functional proliferation readout; correlative analysis between CD160 frequency and restoration magnitude; single lab\",\n      \"pmids\": [\"25255144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Both CD160 isoforms (CD160-GPI and CD160-TM) are expressed in human primary CD4+ and CD8+ T cells and are recognized by HVEM ligand, though binding is less pronounced with CD160-TM. HVEM-specific antibodies block HVEM binding to CD160-GPI but enhance HVEM binding to CD160-TM (suggesting antibody-mediated HVEM multimerization or conformational changes facilitate CD160-TM binding). Triggering CD160-GPI on Jurkat cells with bead-bound HVEM-Fc or anti-CD160 mAb enhances cell activation (positive costimulatory role). CD160-GPI-specific antibodies combined with PD-1 blockade synergistically enhance HIV-specific CD8+ T cell proliferation.\",\n      \"method\": \"Quantitative RT-PCR, flow cytometry, Time-Resolved Fluorescence binding assay, Jurkat cell activation assays, ex vivo PBMC stimulation with HIV antigens, antibody blocking experiments\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assay demonstrating differential isoform-HVEM interaction, combined with functional activation assays; single lab with multiple methods\",\n      \"pmids\": [\"25179432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD160 is essential for NK cell IFN-γ production but not cytotoxicity. CD160-deficient mice show severely compromised control of NK-sensitive tumors due to markedly reduced IFN-γ secretion by NK cells (not impaired cytotoxicity). A soluble CD160-Ig fusion protein impairs tumor control and IFN-γ production. Reciprocal bone marrow transfer identifies the intrinsic role of CD160 on NK cells. Intratumoral transfer of CD160+ NK fraction into CD160-/- tumor-bearing mice causes tumor regression.\",\n      \"method\": \"CD160 knockout mouse generation, tumor challenge assays, IFN-γ ELISA/intracellular cytokine staining, cytotoxicity assays, soluble CD160-Ig fusion protein treatment, reciprocal bone marrow transfer, intratumoral cell transfer\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic knockout combined with multiple orthogonal approaches (bone marrow chimera, soluble decoy, adoptive transfer); clear mechanistic separation of IFN-γ production from cytotoxicity\",\n      \"pmids\": [\"25711213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD160 provides costimulatory signals to CD8+ T cells required for optimal effector functions during oral Listeria monocytogenes infection. CD160-/- mice fail to clear oral L. monocytogenes efficiently; this defect is attributable to compromised CD8+ T cells and intraepithelial lymphocytes (not NK cells). CD160-/- CD8+ T cells show reduced granzyme B expression and IFN-γ/TNF-α co-production. Adoptive transfer of CD160-/- CD8+ T cells into RAG-/- recipients results in higher mortality, weight loss, and bacterial burden compared to WT CD8+ T cells.\",\n      \"method\": \"CD160 knockout mice, in vivo infection model, flow cytometry (granzyme B, IFN-γ, TNF-α), RAG-/- reconstitution experiments, adoptive transfer\",\n      \"journal\": \"ImmunoHorizons\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple in vivo functional readouts (cytokine, cytotoxic molecule expression, bacterial burden, survival) and adoptive transfer confirming cell-intrinsic role of CD160 on CD8+ T cells\",\n      \"pmids\": [\"31022694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD160 serves as a co-inhibitory receptor on NKT cells that dampens cytokine production during early innate immune activation. CD160-/- mice develop severe liver injury after α-galactosylceramide or Concanavalin A challenge, with hyperactivation of NKT cells, elevated AST/ALT, and enhanced IFN-γ, TNF, and IL-4 production. Mixed bone marrow chimeras show this is NKT cell-intrinsic. CD160 and BTLA serve as non-overlapping negative regulators of NKT cells (anti-BTLA mAb aggravates injury in CD160-/- mice).\",\n      \"method\": \"CD160 knockout mice, mixed bone marrow chimeras, in vivo α-GalCer and ConA challenge, serum ALT/AST measurement, intracellular cytokine staining, anti-BTLA antibody treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with mixed bone marrow chimera (establishing cell-intrinsic role) plus multiple in vivo functional readouts and pharmacological dissection of CD160 vs BTLA pathways\",\n      \"pmids\": [\"31332204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the human CD160 extracellular domain and its complex with human HVEM was determined. CD160 adopts a unique variation of the immunoglobulin fold and exists as a monomer in solution. The CD160:HVEM assembly shows 1:1 stoichiometry with a binding interface similar to the BTLA:HVEM complex, revealing the chemical and physical determinants of CD160-HVEM recognition.\",\n      \"method\": \"X-ray crystallography (crystal structure of CD160 alone and CD160:HVEM complex)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure at atomic resolution defining the binding interface and stoichiometry; directly reveals mechanism of HVEM engagement\",\n      \"pmids\": [\"31230945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of HVEM revealed distinct surfaces that engage LIGHT (TNF ligand) versus BTLA/CD160 (Ig superfamily ligands), including a human HVEM-LIGHT-CD160 ternary complex showing HVEM can interact simultaneously with both LIGHT and CD160. HVEM knockin mutants that selectively recognize either TNF or Ig ligands in mice demonstrate selective functions: LIGHT binding mediates bacterial clearance in the intestine; Ig ligand (BTLA/CD160) binding ameliorates liver inflammation.\",\n      \"method\": \"X-ray crystallography (HVEM alone, HVEM-LIGHT, HVEM-CD160, ternary complex), generation of HVEM knockin mutant mice, in vivo infection/inflammation models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures defining distinct binding surfaces combined with knockin mouse models demonstrating selective in vivo functions; multiple orthogonal approaches in single rigorous study\",\n      \"pmids\": [\"34709351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD160 does not independently induce cytotoxicity but costimulates CD3-redirected killing in 2B4+CD160+ CD8+ T cells. The 2B4+CD160+ subset expresses high amounts of perforin and granzyme B, and CD160 expression increases from naive to terminally differentiated phenotype during CTL ontogeny.\",\n      \"method\": \"Flow cytometry, intracellular perforin/granzyme B staining, CD3-redirected cytotoxicity assays with anti-CD160 mAb, phenotypic analysis of CTL subsets\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay showing CD160 costimulates (but does not independently trigger) cytotoxicity; single lab with flow cytometry and cytotoxicity assays\",\n      \"pmids\": [\"16917959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD160 acts as a co-activator receptor for CD3-induced proliferation of CD4+CD160+ T cells isolated from inflammatory skin lesions. A novel CD4+CD160+ T cell subset was identified infiltrating inflammatory skin lesions (atopic dermatitis, contact dermatitis, psoriasis). CD160 transcripts can be induced in IL-2 or IL-15-activated CD4+ peripheral blood lymphocytes.\",\n      \"method\": \"Immunohistochemistry, CD3-induced proliferation assays with anti-CD160 mAb costimulation, RT-PCR, flow cytometry\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-activation assay in a minor T cell subset from skin lesions; limited mechanistic depth\",\n      \"pmids\": [\"17218942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TGFβ1 interferes with IFN-γ production by CD160+ NK cells; blocking TGFβ1 restores IFN-γ production specifically in CD160+ NK cells to normal levels. Transcriptomic analysis of sorted CD160+ and CD160- NK cells revealed that CD160+ NK cells have functional activation and high IFN-γ production programs.\",\n      \"method\": \"Flow cytometry sorting of CD160+ and CD160- NK cells, gene set enrichment analysis/microarray, TGFβ1 blocking antibody, IFN-γ ELISA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sorted primary human NK cells with transcriptomic profiling plus TGFβ1 blockade functional rescue; single lab with orthogonal methods\",\n      \"pmids\": [\"30232222\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD160 is a GPI-anchored (and alternatively spliced transmembrane) Ig-superfamily receptor expressed on cytotoxic NK cells, CD8+ T cell subsets, and intraepithelial lymphocytes that engages MHC class I molecules (HLA-C) and HVEM as ligands: on NK cells, MHC-I/HLA-C engagement triggers cytotoxicity and cytokine (IFN-γ, TNF-α, IL-6) production through a PI3K–Syk–AKT–ERK signaling cascade (with CD160-TM signaling additionally through p56lck), whereas on CD4+ and CD8+ T cells, HVEM engagement via CD160 delivers a coinhibitory signal that dampens TCR-mediated activation; the crystal structure of the CD160–HVEM complex reveals a 1:1 stoichiometry at the CRD1 surface of HVEM distinct from the LIGHT binding site, and HVEM can simultaneously engage CD160 and LIGHT in a ternary complex, enabling bidirectional regulation of immune responses.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD160 is an immunoglobulin-superfamily receptor expressed on cytotoxic NK cells (CD56dim/CD16+), CD8+CD28- T cell subsets, and intestinal intraepithelial lymphocytes that delivers context-dependent activating or inhibitory signals to control lymphocyte effector function [#0]. It was originally characterized as a cysteine-rich, GPI-anchored protein forming tightly disulfide-linked multimers [#0], with a later-discovered alternatively spliced transmembrane isoform (CD160-TM) restricted to activated NK cells [#5]. On NK cells, CD160 engages MHC class I (HLA-C) and HVEM to trigger cytotoxicity and inflammatory cytokine production through a Syk\\u2013PI3K\\u2013AKT\\u2013ERK signaling cascade, with the CD160-TM cytoplasmic tail signaling via the Src-family kinase p56lck [#1, #3, #5, #9]; this pathway is selectively required for NK-cell IFN-\\u03b3 production rather than cytotoxicity, as shown in CD160-deficient mice that lose control of NK-sensitive tumors [#12]. The same PI3K-dependent survival program is co-opted in chronic lymphocytic leukemia cells, where CD160 activation upregulates Bcl-2/Bcl-xL/Mcl-1 and protects against apoptosis [#6]. On T cells and NKT cells, CD160 engagement of HVEM at its CRD1 surface delivers a coinhibitory signal that dampens TCR-driven activation and innate cytokine output [#4, #14], while the receptor also acts as a costimulator of TCR-redirected killing in differentiated CD8+ effector cells [#2, #17]. Crystallography established that CD160 is a monomeric Ig fold binding HVEM in a 1:1 complex distinct from the LIGHT-binding site, and that HVEM can simultaneously engage LIGHT and CD160 in a ternary complex, providing the structural basis for bidirectional immune regulation [#15, #16]. CD160 is additionally expressed selectively on tumor-associated neovascular endothelium, where antibody targeting causes regression of tumor vasculature [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established CD160 as a distinct molecular entity by cloning it and showing it is a GPI-anchored, multimeric cysteine-rich Ig-like protein with lymphocyte-restricted expression.\",\n      \"evidence\": \"cDNA cloning, reducing/non-reducing immunoprecipitation, RNA blot, and flow cytometry on NK and T cell subsets\",\n      \"pmids\": [\"9743336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand or signaling function defined at this stage\", \"Multimerization stoichiometry of the native receptor not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified MHC class I (HLA-C) as a CD160 ligand whose engagement triggers NK cytolysis, defining CD160 as a functional activating receptor.\",\n      \"evidence\": \"Recombinant soluble HLA-Cw3/CD160 binding plus antibody-blocking cytotoxicity assays\",\n      \"pmids\": [\"12486241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascade not yet mapped\", \"Affinity and physiological relevance of HLA-C binding versus other ligands not quantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed CD160 functions as a TCR co-receptor on CD28-negative CD8+ effector T cells, physically linking it to proximal TCR signaling machinery.\",\n      \"evidence\": \"Anti-CD160 proliferation assays and co-immunoprecipitation with p56lck and phospho-zeta chains\",\n      \"pmids\": [\"11978774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GPI-anchored isoform lacks a cytoplasmic tail, leaving the mechanism of p56lck coupling unexplained\", \"Single-lab co-IP without reciprocal validation\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the NK-cell signaling cascade downstream of CD160 as Syk\\u2192PI3K\\u2192AKT/ERK, explaining how engagement drives both cytotoxicity and cytokine release.\",\n      \"evidence\": \"Pharmacological inhibitors of PI3K/MEK/Syk, confocal co-localization, and phospho-Western blotting in primary human NK cells\",\n      \"pmids\": [\"17307798\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a GPI-anchored receptor recruits Syk/PI3K not resolved\", \"Inhibitor specificity caveats for the kinase assignments\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified HVEM as a second CD160 ligand and reversed the functional picture by showing CD160-HVEM engagement coinhibits T cell activation via the HVEM CRD1 domain.\",\n      \"evidence\": \"HVEM CRD1 deletion mutagenesis with T cell activation/cytokine assays and HVEM-transfected co-culture\",\n      \"pmids\": [\"18193050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of CD160 versus BTLA at shared CRD1 surface not separated\", \"Inhibitory signaling output of CD160 not mechanistically traced\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovered the transmembrane isoform CD160-TM and showed its cytoplasmic tail is sufficient for p56lck-dependent ERK signaling and NK degranulation, providing a signaling-competent form of the receptor.\",\n      \"evidence\": \"RT-PCR isoform characterization, Src-kinase inhibitor experiments, CD107a mobilization assays\",\n      \"pmids\": [\"19109136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative physiological abundance of TM versus GPI isoform unclear\", \"Direct kinase-tail interaction not biochemically demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that CD160-PI3K signaling drives a pro-survival program in CLL cells, extending the activating cascade to a pathological context.\",\n      \"evidence\": \"CLL cell culture with CD160 stimulation, Bcl-2 family Westerns, apoptosis/proliferation assays, PI3K inhibition\",\n      \"pmids\": [\"20164468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand driving CD160 activation in CLL not identified\", \"Connection to the NK Syk\\u2013PI3K cascade not formally established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that HVEM, not other shared ligands, costimulates CD160 on NK cells to enhance cytolysis and cytokine output, contrasting with HVEM-BTLA inhibition.\",\n      \"evidence\": \"NK activation assays, phospho-ERK/AKT Westerns, cytotoxicity and cytokine ELISAs with BTLA as comparator\",\n      \"pmids\": [\"23761635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How identical HVEM engagement yields opposite outcomes on NK (activating) versus T cells (inhibitory) not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked CD160 to T cell exhaustion, showing CD160/PD-1 co-expression marks dysfunctional HIV-specific CD8 T cells and that CD160/HVEM blockade restores function.\",\n      \"evidence\": \"Flow phenotyping, HVEM-blocking functional assays, transcriptional profiling of exhausted T cells\",\n      \"pmids\": [\"22916009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CD160 acts via HVEM exclusively in exhaustion not isolated\", \"Correlation versus causation in the exhaustion signature\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved that CD160-mediated CD8 T cell suppression operates independently of PD-1 and is not activation-induced, distinguishing it from the canonical exhaustion checkpoint.\",\n      \"evidence\": \"Anti-CD160 blocking with proliferation/perforin readouts across influenza/EBV/CMV-specific T cells\",\n      \"pmids\": [\"25255144\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The CD160 ligand operative in these settings not pinned down\", \"Correlative restoration data\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed both CD160 isoforms bind HVEM with differing efficiency and that CD160-GPI triggering can deliver a positive costimulatory signal, underscoring the receptor's bidirectional output.\",\n      \"evidence\": \"Time-resolved fluorescence binding, Jurkat activation assays, antibody-blocking and HIV-antigen PBMC stimulation\",\n      \"pmids\": [\"25179432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for isoform-dependent HVEM binding differences unresolved\", \"Single-lab functional assays\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Used genetic knockout to dissociate CD160 functions, proving it is intrinsically required for NK-cell IFN-\\u03b3 production but dispensable for cytotoxicity in tumor control.\",\n      \"evidence\": \"CD160-/- mice, tumor challenge, bone marrow chimeras, soluble CD160-Ig decoy, intratumoral NK transfer\",\n      \"pmids\": [\"25711213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand driving the in vivo NK IFN-\\u03b3 response not defined\", \"Reconciliation with earlier reports of CD160-driven cytotoxicity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a cell-intrinsic costimulatory role for CD160 on CD8 T cells and IELs during oral Listeria infection, revealing a protective effector function in vivo.\",\n      \"evidence\": \"CD160-/- infection model, granzyme B/IFN-\\u03b3/TNF flow cytometry, RAG-/- adoptive transfer\",\n      \"pmids\": [\"31022694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Costimulatory versus coinhibitory role context-dependence not mechanistically explained\", \"Ligand engaged during mucosal infection unidentified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established CD160 as a non-redundant coinhibitory receptor on NKT cells that limits innate cytokine-driven liver injury, parallel to but distinct from BTLA.\",\n      \"evidence\": \"CD160-/- mice, mixed bone marrow chimeras, \\u03b1-GalCer/ConA challenge, anti-BTLA dissection\",\n      \"pmids\": [\"31332204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitory signaling mechanism in NKT cells not traced\", \"How CD160 and BTLA divide labor at shared HVEM not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the atomic-level basis for CD160-HVEM recognition, showing CD160 is a monomeric Ig fold binding HVEM 1:1 at an interface resembling BTLA:HVEM.\",\n      \"evidence\": \"X-ray crystallography of CD160 alone and the CD160:HVEM complex\",\n      \"pmids\": [\"31230945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of monomeric solution behavior with earlier disulfide-multimer biochemistry\", \"Structure does not explain divergent signaling outputs\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined how HVEM coordinates competing ligands, showing distinct surfaces for LIGHT versus CD160/BTLA, a ternary LIGHT-HVEM-CD160 complex, and selective in vivo functions of each axis.\",\n      \"evidence\": \"Crystal structures (HVEM, HVEM-LIGHT, HVEM-CD160, ternary) plus HVEM ligand-selective knockin mice in infection/inflammation models\",\n      \"pmids\": [\"34709351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of simultaneous LIGHT/CD160 occupancy on the same HVEM not directly tested\", \"Whether ternary complex forms physiologically in tissue\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked CD160+ NK cells to a high-IFN-\\u03b3 functional program suppressed by TGF\\u03b21, identifying a microenvironmental brake on CD160-driven NK activation.\",\n      \"evidence\": \"Sorted CD160+/- NK transcriptomics, GSEA, and TGF\\u03b21-blocking IFN-\\u03b3 rescue\",\n      \"pmids\": [\"30232222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of TGF\\u03b21 interference with CD160 signaling not defined\", \"Correlative transcriptomics\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed a non-lymphocyte role for CD160 as a marker of tumor neovascular endothelium and a therapeutic anti-angiogenic target.\",\n      \"evidence\": \"Immunohistochemistry and anti-CD160 antibody across rabbit cornea, retinopathy, Matrigel, and melanoma models\",\n      \"pmids\": [\"21482699\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endothelial CD160 ligand and signaling mechanism unknown\", \"Relationship to lymphocyte CD160 function unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single receptor delivers opposite (activating versus inhibitory) signals depending on cell type and ligand, and how GPI-anchored CD160 lacking a cytoplasmic tail couples to intracellular kinases.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or biochemical mechanism for GPI-isoform signal transduction\", \"No unified model reconciling costimulatory and coinhibitory outcomes\", \"Ligand(s) governing each functional context not fully mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 4, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 14, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 4, 9, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 9, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HVEM\", \"HLA-C\", \"LCK\", \"LIGHT\", \"BTLA\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}